XPHYF News and Press, XPhyto Therapeutics Corp From 05/20/21

Rapid 25-minute point-of-care COVID-19 PCR test available for purchase in Germany commencing May 25, 2021 Volume based pricing competitive with other COVID-19 PCR test products on the market Initial manufacturing capacity secured, additional capacity to increase based on demand ...

XPhyto recently delivered 2,000 of its rapid Covid-ID Lab test kits to an established Israeli distributor for clinical evaluation by the Ministry of Health The delivery, which marks entry into the Middle East, follows the approval of the test kits in Europe In an earlier interview, CE...

The House of Representatives in Texas passed a bill last week that would mandate the state to undertake research regarding the potential of different psychedelic substances, such as MDMA and psilocybin. The bill, whose chief sponsor was Rep. Alex Dominguez, a Democrat, was supported by 134...

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience technology accelerator, recently entered a strategic distribution, storage and logistics agreement for its commercial 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”). In April, XPhyto announced its...

Long before lawmakers were considering legislation that would federally decriminalize cannabis, Congress passed the 2018 Farm Bill. Among other things, this legislation legalized the cultivation and sale of industrial hemp and its derivatives. Hemp is a form of cannabis that has less than 0....

A study conducted by researchers from Baylor College of Medicine has found that intermittent fasting (“IF”) has the potential to decrease hypertension by restructuring gut microbiome. Hypertension increases an individual’s risk for getting a stroke or cardiovascular ...

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator at the leading-edge of the life science industry,released an update on its 2021 drug formulation programs, noting that the programs are advancing on schedule and expanding in scope. The companyȁ...

Rotigotine transdermal human pilot study successfully completed; program advancing to pivotal study Land purchased for construction of commercial drug manufacturing facility in Germany VANCOUVER, BC & BIBERACH, GERMANY / ACCESSWIRE / May 13, 2021 / XPhyto Therapeutics Corp. ...

Psychedelics are making a comeback in Western society , having started the journey to mainstream a few years ago. This renaissance has brought with it a lot of new discoveries, many of which are useful for the mental health field. As mental health disorders increase at a rather alarming r...

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) director and CEO Hugh Rogers was a featured guest on two different video interviews. In both interviews, Rogers shared key information and updates about XPhyto, a bioscience accelerator focused on next-generation drug delivery,...